Abbvie’s antihypertensive, Tarka, was a combination therapy of an ACE inhibitor + a calcium channel blocker (CCB). This unbranded software helped account managers demonstrate the economic costs of proteinuria among diabetic patients with and without hypertension. It also explored the potential for savings with a management strategy that included a nondihydropyridine CCB for members with diabetes and hypertension.